·Drug development decision makers need In rely on robust rationale to select drug candidates, targets, trial designs, dose regimens, patient populations and suitable endpoint measures etc.·A lack of informed decision making has detrimental effects to patients,discovery and development program choices, and will incur significant financial inefficiencies ·Multiple stakeholders seek greater transparency and clinical trial data sharing ·Approaches such as Model-Informed Drug Discovery and Development (MID3) are essential to perform knowledge integration ·Model-Informed Drug Discovery and Development provides a quantitative basis for informed risk assessments